美多巴单用及联合二氢麦角隐亭治疗帕金森病的临床疗效

Clinical efficacy of dihydroergocryptine combined with madopar in the treatment of Parkinson's disease

目的探讨兰美多巴单用及联合二氢麦角隐亭治疗帕金森病的临床疗效。方法选择我院收治的中晚期帕金森病患者94例,随机分为观察组和对照组,2组均给予美多巴进行治疗,观察组联合给予二氢麦角隐亭治疗,比较2组临床治疗效果。结果观察组总有效率为74.47%,对照组总有效率为46.81%,2组治疗效果比较经统计学分析比较,差异有统计学意义(P<0.05)。2组治疗后帕金森氏病综合评分均较治疗前降低,观察组较对照组明显,经统计学分析比较,差异有统计学意义(P<0.05)。2组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论美多巴联合二氢麦角隐亭治疗中、晚期帕金森病疗效满意且安全,值得临床推广使用。

Objective To investigate the clinical effect of LAN madopar monotherapy and combined with dihydroergocryp- tine in the treatment of Parkinson＇s disease and its application value. Methods Totally 94 patients with advanced Parkinson＇s disease in our hospital were randomly divided into observation group and control group, two groups were given Madopar treat- ment, the observation group treated by dihydroergocryptine, the clinical therapeutic effect of two groups were observed. Re- sults The total effective rate of observation group was 74.47%, which in control group was 46.81%, the difference was statistically significant （P〈0.05）. The unified Parkinson disease rating of two groups after treatment were lower than that before treatment, the observation group decreased significantly compared with control group, the difference was statistically significant （P〈0.05）. The incidence of adverse reactions of the two groups had no significant difference （P〉0.05）. Conclusion Madopar combined with dihydroergocryptine therapy in advanced Parkinson＇s disease is reliable and safe, which is worth popu-larizing in clinical use.